2020
DOI: 10.1016/j.csbj.2020.09.008
|View full text |Cite
|
Sign up to set email alerts
|

Mitochondria under the spotlight: On the implications of mitochondrial dysfunction and its connectivity to neuropsychiatric disorders

Abstract: Graphical abstract

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
4
4

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 147 publications
(175 reference statements)
0
10
0
Order By: Relevance
“…Because BLM-s is localized in the mitochondria [ 31 ], depletion of BLM-s could potentially affect mitochondrial physiology in the limbic system, which in turn causes dysfunctional mood control. Further exploration of BLM-s’ role in mitochondria would be interesting, given that drugs targeting mitochondria physiology are currently investigated as a potential pharmaceutical target for the treatment-resistant major depressive disorder [ 60 ].…”
Section: Discussionmentioning
confidence: 99%
“…Because BLM-s is localized in the mitochondria [ 31 ], depletion of BLM-s could potentially affect mitochondrial physiology in the limbic system, which in turn causes dysfunctional mood control. Further exploration of BLM-s’ role in mitochondria would be interesting, given that drugs targeting mitochondria physiology are currently investigated as a potential pharmaceutical target for the treatment-resistant major depressive disorder [ 60 ].…”
Section: Discussionmentioning
confidence: 99%
“…Machine learning-based decision-making tools are also used to screen and discover new treatments/drugs to treat neuropsychiatric disorders by analyzing the different biomarkers (genetic and biochemical) and molecules to chemical reactions. This approach could also help identify the best treatment for each patient by analyzing the treatment response from each patient, so-called precision medicine (85).…”
Section: Machine Learning Tools For Future Studies and Therapeutic Treatment Developmentmentioning
confidence: 99%
“…To shed light on database overlaps and discrepancies, we have recently surveyed ( Zilocchi et al., 2020 ) five established databases ( Figure 1 A and Table S1 ) and extracted their mt protein inventory, including MitoCarta2.0 ( Calvo et al., 2016 ), Integrated Mitochondrial Protein Index (IMPI) ( Smith and Robinson, 2019 ), UniProt ( UniProt, 2019 ), Gene Ontology (GO) ( The Gene Ontology Consortium, 2019 ), and COMPARTMENTS ( Binder et al., 2014 ). Although databases such as IMPI and COMPARTMENTS share 1,197 mt proteins in common, MitoCarta2.0 and UniProt only share 877 mt proteins, with 647 proteins shared between all five databases ( Figure 1 A).…”
Section: A Systems Perspective Of Mt Proteins In Rdsmentioning
confidence: 99%
“…In addition, artificial intelligence is also being rapidly integrated to model diseased human cells, which can overcome the scarcity of RD samples. Examining these models can vary based on nutrient, lipid, and metabolite to suggest potential molecules of therapeutic value solely based on machine learning algorithms that stratify and match patients and prioritize in silico -examined therapeutic options ( Zilocchi et al., 2020 ). This can help clinicians involved in RDs to find their needle in the haystack, and with more contributions from the scientific and clinician community, more tools, methods, and databases can be developed to accelerate RD therapeutic developments.…”
Section: Genotypic and Phenotypic Matchmaking Toolsmentioning
confidence: 99%